Accelerate Diagnostics (NASDAQ:AXDX) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a sell rating to a hold rating in a report published on Monday.

Accelerate Diagnostics Stock Down 2.4 %

AXDX stock opened at $1.61 on Monday. The company has a market cap of $40.31 million, a price-to-earnings ratio of -0.57 and a beta of 0.59. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $5.23. The company has a 50 day moving average of $1.80 and a two-hundred day moving average of $1.51.

Institutional Trading of Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. 17.14% of the stock is currently owned by institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.